Directed new share issue in Hansa Biopharma AB (SE) — SEK 372 million Healthcare Directed new share issue in Hansa Biopharma AB (SE) — SEK 372 million
Recommended voluntary public cash offer to shareholders in Byggfakta Group Nordic Holdco AB — SEK 10.1 billion TMT Recommended voluntary public cash offer to shareholders in Byggfakta Group Nordic Holdco AB — SEK 10.1 billion
Extension of credit facilities and Rights issue in Nobia AB (SE) — SEK 1,262 million Consumer & Retail Extension of credit facilities and Rights issue in Nobia AB (SE) — SEK 1,262 million
Directed new share issue in Ferroamp AB (SE) — SEK 39 million Cleantech, Renewables & Infrastructure Directed new share issue in Ferroamp AB (SE) — SEK 39 million
Voluntary recommended public cash tender offer for all the shares and stock options in Efecte Plc — EUR 100 million TMT Voluntary recommended public cash tender offer for all the shares and stock options in Efecte Plc — EUR 100 million
Rights issue in Vimian AB (SE) — SEK 1,633 million Healthcare Rights issue in Vimian AB (SE) — SEK 1,633 million
Directed share issue in Faron Pharmaceuticals Ltd (FI) — EUR 4.8 million Healthcare Directed share issue in Faron Pharmaceuticals Ltd (FI) — EUR 4.8 million
Rights issue in Acconeer AB (SE) — SEK 149 million TMT Rights issue in Acconeer AB (SE) — SEK 149 million
Divestment of selected assets from Saber Interactive Inc. (US) by Embracer Group AB (SE) — SEK 2,527 million TMT Divestment of selected assets from Saber Interactive Inc. (US) by Embracer Group AB (SE) — SEK 2,527 million
Directed share issue in Irisity AB (SE) – SEK 45 million TMT Directed share issue in Irisity AB (SE) – SEK 45 million
Directed share issue in XXL ASA (NO) – NOK 500 million Consumer & Retail Directed share issue in XXL ASA (NO) – NOK 500 million